PMID- 29707032
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220317
IS  - 1741-427X (Print)
IS  - 1741-4288 (Electronic)
IS  - 1741-427X (Linking)
VI  - 2018
DP  - 2018
TI  - Chromium-Containing Traditional Chinese Medicine, Tianmai Xiaoke Tablet, for 
      Newly Diagnosed Type 2 Diabetes Mellitus: A Meta-Analysis and Systematic Review 
      of Randomized Clinical Trials.
PG  - 3708637
LID - 10.1155/2018/3708637 [doi]
LID - 3708637
AB  - OBJECTIVE: Chromium-containing traditional Chinese medicine Tianmai Xiaoke tablet 
      (TMXKT) is approved for treating newly diagnosed type 2 diabetes mellitus (T2DM) 
      in China. This review aimed to compile the evidence from randomized clinical 
      trials (RCTs) and quantify the effects of TMXKT on newly diagnosed T2DM. METHODS: 
      Seven online databases were investigated up to March 20, 2017. The meta-analysis 
      included RCTs investigating the treatment of newly diagnosed T2DM, in which TMXKT 
      combined with conventional therapy was compared with placebo or conventional 
      therapy. The risk of bias was evaluated using the Cochrane Collaboration tool. 
      The estimated mean difference (MD) and the standardized mean difference were 
      within 95% confidence intervals (CI) with respect to the interstudy 
      heterogeneity. The outcomes were measured using fasting blood glucose (FBG), 2-h 
      postprandial blood glucose (2hPG), glycosylated hemoglobin A1c (HbA1c), and body 
      mass index (BMI) levels. RESULTS: TMXKT combined with conventional therapy 
      lowered FBG level (MD = -0.68, 95% CI -0.90 to -0.45, P < 0.00001), 2hPG (MD = 
      -1.33, 95% CI -1.86 to -0.79, P < 0.00001), HbA1c (MD = -0.46, 95% CI -0.57 to 
      -0.36, P < 0.00001), and BMI (MD = -0.77, 95% CI -1.12 to -0.41, P < 0.00001). 
      CONCLUSIONS: TMXKT combined with conventional therapy is beneficial for patients 
      with newly diagnosed T2DM. However, the effectiveness and safety of TMXKT are 
      uncertain because of the limited number of trials and low methodological quality. 
      Therefore, practitioners should be cautious when applying TMXKT in daily 
      practice. Also, well-designed clinical trials are needed in the future.
FAU - Gu, Yuming
AU  - Gu Y
AD  - Shandong University of Traditional Chinese Medicine, Jinan 250355, China.
FAU - Xu, Xuemin
AU  - Xu X
AD  - Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan 
      250011, China.
FAU - Wang, Zhe
AU  - Wang Z
AD  - Shandong University of Traditional Chinese Medicine, Jinan 250355, China.
FAU - Xu, Yunsheng
AU  - Xu Y
AD  - Second Affiliated Hospital of Shandong University of Traditional Chinese 
      Medicine, Jinan 250001, China.
FAU - Liu, Xiuzhi
AU  - Liu X
AD  - Jinan Municipal Hospital of Traditional Chinese Medicine, Jinan 250012, China.
FAU - Cao, Lejun
AU  - Cao L
AD  - Jinan Municipal Hospital of Traditional Chinese Medicine, Jinan 250012, China.
FAU - Wang, Xueyang
AU  - Wang X
AD  - Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.
FAU - Li, Zhengxin
AU  - Li Z
AD  - Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.
FAU - Feng, Bo
AU  - Feng B
AUID- ORCID: 0000-0002-8128-8127
AD  - Shandong Province Qianfoshan Hospital, Shandong University, Jinan 250014, China.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20180307
PL  - United States
TA  - Evid Based Complement Alternat Med
JT  - Evidence-based complementary and alternative medicine : eCAM
JID - 101215021
PMC - PMC5863285
EDAT- 2018/05/01 06:00
MHDA- 2018/05/01 06:01
PMCR- 2018/03/07
CRDT- 2018/05/01 06:00
PHST- 2017/09/13 00:00 [received]
PHST- 2018/01/29 00:00 [accepted]
PHST- 2018/05/01 06:00 [entrez]
PHST- 2018/05/01 06:00 [pubmed]
PHST- 2018/05/01 06:01 [medline]
PHST- 2018/03/07 00:00 [pmc-release]
AID - 10.1155/2018/3708637 [doi]
PST - epublish
SO  - Evid Based Complement Alternat Med. 2018 Mar 7;2018:3708637. doi: 
      10.1155/2018/3708637. eCollection 2018.